Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone

J. Čermák, S. Pietrucha, A. Nawka, P. Lipone, A. Ruggieri, A. Bonelli, A. Comandini, A. Cattaneo

. 2023 ; 14 (-) : 1127511. [pub] 20230324

Status not-indexed Language English Country Switzerland

Document type Journal Article

This 8-week study was designed to explore any correlation between a passive data collection approach using a wearable device (i.e., digital phenotyping), active data collection (patient's questionnaires), and a traditional clinical evaluation [Montgomery-Åsberg Depression Rating Scale (MADRS)] in patients with major depressive disorder (MDD) treated with trazodone once a day (OAD). Overall, 11 out of 30 planned patients were enrolled. Passive parameters measured by the wearable device included number of steps, distance walked, calories burned, and sleep quality. A relationship between the sleep score (derived from passively measured data) and MADRS score was observed, as was a relationship between data collected actively (assessing depression, sleep, anxiety, and warning signs) and MADRS score. Despite the limited sample size, the efficacy and safety results were consistent with those previously reported for trazodone. The small population in this study limits the conclusions that can be drawn about the correlation between the digital phenotyping approach and traditional clinical evaluation; however, the positive trends observed suggest the need to increase synergies among clinicians, patients, and researchers to overcome the cultural barriers toward implementation of digital tools in the clinical setting. This study is a step toward the use of digital data in monitoring symptoms of depression, and the preliminary data obtained encourage further investigations of a larger population of patients monitored over a longer period of time.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010120
003      
CZ-PrNML
005      
20230721095323.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpsyt.2023.1127511 $2 doi
035    __
$a (PubMed)37032913
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Čermák, Jan $u Psychiatrie Říčany s.r.o., Říčany, Czechia
245    13
$a An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone / $c J. Čermák, S. Pietrucha, A. Nawka, P. Lipone, A. Ruggieri, A. Bonelli, A. Comandini, A. Cattaneo
520    9_
$a This 8-week study was designed to explore any correlation between a passive data collection approach using a wearable device (i.e., digital phenotyping), active data collection (patient's questionnaires), and a traditional clinical evaluation [Montgomery-Åsberg Depression Rating Scale (MADRS)] in patients with major depressive disorder (MDD) treated with trazodone once a day (OAD). Overall, 11 out of 30 planned patients were enrolled. Passive parameters measured by the wearable device included number of steps, distance walked, calories burned, and sleep quality. A relationship between the sleep score (derived from passively measured data) and MADRS score was observed, as was a relationship between data collected actively (assessing depression, sleep, anxiety, and warning signs) and MADRS score. Despite the limited sample size, the efficacy and safety results were consistent with those previously reported for trazodone. The small population in this study limits the conclusions that can be drawn about the correlation between the digital phenotyping approach and traditional clinical evaluation; however, the positive trends observed suggest the need to increase synergies among clinicians, patients, and researchers to overcome the cultural barriers toward implementation of digital tools in the clinical setting. This study is a step toward the use of digital data in monitoring symptoms of depression, and the preliminary data obtained encourage further investigations of a larger population of patients monitored over a longer period of time.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pietrucha, Slavomír $u Centrum Duševního Zdraví-Psychiatrie s.r.o., Kutná Hora, Czechia
700    1_
$a Nawka, Alexander $u Institut Neuropsychiatrické Péče (INEP) (Psychiatric Outpatient Clinic), Praha, Czechia
700    1_
$a Lipone, Paola $u Angelini Pharma S.p.A., Rome, Italy
700    1_
$a Ruggieri, Alessandro $u Angelini Pharma S.p.A., Rome, Italy
700    1_
$a Bonelli, Annalisa $u Angelini Pharma S.p.A., Rome, Italy
700    1_
$a Comandini, Alessandro $u Angelini Pharma S.p.A., Rome, Italy
700    1_
$a Cattaneo, Agnese $u Angelini Pharma S.p.A., Rome, Italy
773    0_
$w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 14, č. - (2023), s. 1127511
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37032913 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095317 $b ABA008
999    __
$a ok $b bmc $g 1958638 $s 1196384
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1127511 $e 20230324 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
LZP    __
$a Pubmed-20230707

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...